# Ascent Solar Technologies, Inc.: financial statements, quarterly

ASTI · Nasdaq · CIK 1350102 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/asti.md) · [Financials](/companies/asti/financials.md) · [Filings](/companies/asti/filings.md) · [Insiders](/companies/asti/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/asti/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [230](/filings/0000950170-24-127076.md) | [2.8 d](/filings/0000950170-25-047692.md) | [5.6](/filings/0000950170-25-071487.md) | [27.7](/filings/0001193125-25-179058.md) | [8.6](/filings/0001193125-25-274376.md) | [0.0 d](/filings/0001193125-26-117839.md) | [15.6](/filings/0001193125-26-214748.md) | [17.0](/filings/0001193125-26-338219.md) | [28.5](/filings/0001193125-25-274376.md) | [15.6 d](/filings/0001193125-26-117839.md) | [51.9](/filings/0001193125-26-214748.md) | [95.2](/filings/0001193125-26-338219.md) |
| Research and development | $k | [345](/filings/0000950170-24-127076.md) | [389 d](/filings/0000950170-25-047692.md) | [607](/filings/0000950170-25-071487.md) | [506](/filings/0001193125-25-179058.md) | [604](/filings/0001193125-25-274376.md) | [584 d](/filings/0001193125-26-117839.md) | [559](/filings/0001193125-26-214748.md) | [623](/filings/0001193125-26-338219.md) | [621](/filings/0001193125-25-274376.md) | [648 d](/filings/0001193125-26-117839.md) | [694](/filings/0001193125-26-214748.md) | [697](/filings/0001193125-26-338219.md) |
| Selling, general and administrative | $k | [1,407](/filings/0000950170-24-127076.md) | [1,186 d](/filings/0000950170-25-047692.md) | [1,060](/filings/0000950170-25-071487.md) | [1,611](/filings/0001193125-25-179058.md) | [1,217](/filings/0001193125-25-274376.md) | [618 d](/filings/0001193125-26-117839.md) | [951](/filings/0001193125-26-214748.md) | [1,033](/filings/0001193125-26-338219.md) | [1,003](/filings/0001193125-25-274376.md) | [1,104 d](/filings/0001193125-26-117839.md) | [1,440](/filings/0001193125-26-214748.md) | [1,072](/filings/0001193125-26-338219.md) |
| Operating income | $k | [(2,378)](/filings/0000950170-24-127076.md) | [(5,089) d](/filings/0000950170-25-047692.md) | [(2,476)](/filings/0000950170-25-071487.md) | [(2,356)](/filings/0001193125-25-179058.md) | [(2,261)](/filings/0001193125-25-274376.md) | [(1,445) d](/filings/0001193125-26-117839.md) | [(1,746)](/filings/0001193125-26-214748.md) | [(2,089)](/filings/0001193125-26-338219.md) | [(1,968)](/filings/0001193125-25-274376.md) | [(2,071) d](/filings/0001193125-26-117839.md) | [(2,262)](/filings/0001193125-26-214748.md) | [(1,946)](/filings/0001193125-26-338219.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(1,909)](/filings/0000950170-24-127076.md) | [(5,164) d](/filings/0000950170-25-047692.md) | [(2,538)](/filings/0001193125-25-179058.md) | [(3,446)](/filings/0001193125-25-179058.md) | [(1,691)](/filings/0001193125-25-274376.md) | [(1,456) d](/filings/0001193125-26-117839.md) | [(1,674)](/filings/0001193125-26-338219.md) | [(2,065)](/filings/0001193125-26-338219.md) | [(2,022)](/filings/0001193125-25-274376.md) | [(2,071) d](/filings/0001193125-26-117839.md) | [(2,177)](/filings/0001193125-26-338219.md) | [(1,827)](/filings/0001193125-26-338219.md) |
| Diluted EPS | $ per share | [(404.00)](/filings/0000950170-24-127076.md) | not reported | [(53.00)](/filings/0000950170-25-071487.md) | [(6.76)](/filings/0001193125-25-179058.md) | [(1.37)](/filings/0001193125-25-274376.md) | not reported | [(1.13)](/filings/0001193125-26-214748.md) | [(1.17)](/filings/0001193125-26-338219.md) | [(0.62)](/filings/0001193125-25-274376.md) | not reported | [(0.27)](/filings/0001193125-26-214748.md) | [(0.19)](/filings/0001193125-26-338219.md) |
| Basic EPS | $ per share | [(404.00)](/filings/0000950170-24-127076.md) | not reported | [(53.00)](/filings/0000950170-25-071487.md) | [(6.76)](/filings/0001193125-25-179058.md) | [(1.37)](/filings/0001193125-25-274376.md) | not reported | [(1.13)](/filings/0001193125-26-214748.md) | [(1.17)](/filings/0001193125-26-338219.md) | [(0.62)](/filings/0001193125-25-274376.md) | not reported | [(0.27)](/filings/0001193125-26-214748.md) | [(0.19)](/filings/0001193125-26-338219.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.2](/filings/0000950170-23-063715.md) | [1.0](/filings/0000950170-25-047692.md) | [0.2](/filings/0000950170-24-056951.md) | [5.8](/filings/0000950170-24-091911.md) | [3.7](/filings/0000950170-24-127076.md) | [3.2](/filings/0001193125-26-117839.md) | [2.3](/filings/0000950170-25-071487.md) | [3.0](/filings/0001193125-25-179058.md) | [2.1](/filings/0001193125-25-274376.md) | [2.8](/filings/0001193125-26-338219.md) | [16.1](/filings/0001193125-26-214748.md) | [14.5](/filings/0001193125-26-338219.md) |
| Current assets | $m | [3.1](/filings/0000950170-23-063715.md) | [1.5](/filings/0000950170-25-047692.md) | [0.9](/filings/0000950170-24-056951.md) | [6.4](/filings/0000950170-24-091911.md) | [4.3](/filings/0000950170-24-127076.md) | [3.7](/filings/0001193125-26-117839.md) | [2.9](/filings/0000950170-25-071487.md) | [3.6](/filings/0001193125-25-179058.md) | [2.7](/filings/0001193125-25-274376.md) | [3.4](/filings/0001193125-26-338219.md) | [16.8](/filings/0001193125-26-214748.md) | [15.3](/filings/0001193125-26-338219.md) |
| Total assets | $m | [11.2](/filings/0000950170-23-063715.md) | [6.3](/filings/0000950170-25-047692.md) | [5.0](/filings/0000950170-24-056951.md) | [10.2](/filings/0000950170-24-091911.md) | [7.9](/filings/0000950170-24-127076.md) | [7.1](/filings/0001193125-26-117839.md) | [6.2](/filings/0000950170-25-071487.md) | [6.8](/filings/0001193125-25-179058.md) | [5.8](/filings/0001193125-25-274376.md) | [6.3](/filings/0001193125-26-338219.md) | [19.8](/filings/0001193125-26-214748.md) | [18.1](/filings/0001193125-26-338219.md) |
| Current liabilities | $m | [11.9](/filings/0000950170-23-063715.md) | [5.8](/filings/0000950170-25-047692.md) | [5.6](/filings/0000950170-24-056951.md) | [4.2](/filings/0000950170-24-091911.md) | [3.0](/filings/0000950170-24-127076.md) | [2.3](/filings/0001193125-26-117839.md) | [2.3](/filings/0000950170-25-071487.md) | [2.2](/filings/0001193125-25-179058.md) | [2.2](/filings/0001193125-25-274376.md) | [2.2](/filings/0001193125-26-338219.md) | [2.4](/filings/0001193125-26-214748.md) | [2.4](/filings/0001193125-26-338219.md) |
| Total liabilities | $m | [14.1](/filings/0000950170-23-063715.md) | [7.8](/filings/0000950170-25-047692.md) | [7.5](/filings/0000950170-24-056951.md) | [6.0](/filings/0000950170-24-091911.md) | [4.6](/filings/0000950170-24-127076.md) | [3.8](/filings/0001193125-26-117839.md) | [3.6](/filings/0000950170-25-071487.md) | [3.4](/filings/0001193125-25-179058.md) | [3.1](/filings/0001193125-25-274376.md) | [3.0](/filings/0001193125-26-338219.md) | [3.0](/filings/0001193125-26-214748.md) | [2.8](/filings/0001193125-26-338219.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | [0.4](/filings/0000950170-25-047692.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(2.9)](/filings/0000950170-24-127076.md) | [(1.5)](/filings/0001193125-26-117839.md) | [(2.6)](/filings/0001193125-25-179058.md) | [4.2](/filings/0001193125-25-274376.md) | [(3.3)](/filings/0001193125-25-274376.md) | [3.4](/filings/0001193125-26-338219.md) | [2.6](/filings/0001193125-26-338219.md) | [3.4](/filings/0001193125-26-338219.md) | [2.7](/filings/0001193125-25-274376.md) | [3.3](/filings/0001193125-26-338219.md) | [16.8](/filings/0001193125-26-338219.md) | [15.3](/filings/0001193125-26-338219.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:DebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(752) d](/filings/0000950170-24-127076.md) | [(2,207) d](/filings/0000950170-25-047692.md) | [(1,198)](/filings/0000950170-25-071487.md) | [(3,649) d](/filings/0001193125-25-179058.md) | [(2,051) d](/filings/0001193125-25-274376.md) | [(1,526) d](/filings/0001193125-26-117839.md) | [(1,550)](/filings/0001193125-26-214748.md) | [(1,812) d](/filings/0001193125-26-338219.md) | [(1,736) d](/filings/0001193125-25-274376.md) | [(1,807) d](/filings/0001193125-26-117839.md) | [(2,020)](/filings/0001193125-26-214748.md) | [(1,789) d](/filings/0001193125-26-338219.md) |
| Capital expenditure | $k | [3.3 d](/filings/0000950170-24-127076.md) | [13.1 d](/filings/0000950170-25-047692.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-117839.md) | [0.5](/filings/0001193125-26-214748.md) | [2.0 d](/filings/0001193125-26-338219.md) | [29.5 d](/filings/0001193125-25-274376.md) | [0.0 d](/filings/0001193125-26-117839.md) | [0.0](/filings/0001193125-26-214748.md) | [0.0 d](/filings/0001193125-26-338219.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [166](/filings/0000950170-23-063715.md) | [178](/filings/0000950170-24-056951.md) | [234](/filings/0000950170-24-091911.md) | [4.7](/filings/0000950170-24-127076.md) | [47.6](/filings/0000950170-25-071487.md) | [510](/filings/0001193125-25-179058.md) | [1,232](/filings/0001193125-25-274376.md) | [1,487](/filings/0001193125-26-214748.md) | [1,803](/filings/0001193125-26-338219.md) | [3,164](/filings/0001193125-25-274376.md) | [7,969](/filings/0001193125-26-214748.md) | [9,587](/filings/0001193125-26-338219.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 9,816,431 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001193125-26-338219.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.